Skip to content
Friday 21 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,816.56
+0.64%
DAX
26,128.55
+0.56%
CAC 40
8,484.43
+0.37%
STOXX 50
6,458.11
+0.56%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 15 April 2015 12:07 pm

New discovery in mice paves the way for dementia cure

By: Sarah Spickernell

Add as a preferred source on Google

Scientists at Duke University in the US have managed to stop mice developing dementia, and a similar cure could soon be on its way for humans.

Using a drug that tinkers with the rodent's immune system, they were able to completely stop the onset of the age-related disorder, which is characterised by loss of memory and a general decline in cognitive ability.
 
The cells they focussed on are called microglia, which are normally the first line of defence in the brain and spinal cord. But in the case of dementia they become the enemy themselves, and start breaking down too much argenine – an essential amino acid for building proteins in our bodies.
 
The drug contained a chemical block that was able to stop the microglia from working properly, and 
as a result the amount of argenine stayed at a healthy level. When this happened, the scientists noticed fewer symptoms of dementia, such as a build up of damaged protein in the brain and poor performance in memory tests. 
 
Dementia is a broad spectrum of degenerative brain diseases, one of which is Alzheimer's, and according to lead researcher Matthew Kan this sheds a very positive light on the development of new treatments and maybe even a cure for the disease.
 
“All of this suggests to us that if you can block this local process of amino acid deprivation, then you can protect the mouse, at least from Alzheimer's disease,” he told the BBC.
 
"We see this study opening the doors to thinking about Alzheimer's in a completely different way, to break the stalemate of ideas in Alzheimer's disease."

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • As it happened: Miners fuel FTSE 100 recovery; oil jumps as Trump claims Strait of Hormuz

  • City law firm sues prominent Emirati business family

  • Amanda Blanc has worked her magic at Aviva

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

    Business Wire
  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

    FTSE 100 Live
    Donald Trump speaking at a podium, microphone visible, discussing the Strait of Hormuz
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Row erupts over Tory plan to stop Soho pub goers standing up 

    Hospitality
    Bustling Soho street scene with vibrant storefronts, diverse pedestrians, and iconic London architecture under clear skies
  • Iksuda receives US FDA IND clearance for IKS04

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Chelsea fined £10m, avoid points penalty and receive Mykhailo Mudryk boost

    Sport Business
    A male Chelsea FC player, possibly Mykhailo Mudryk, in a blue and black long-sleeved training top, stretching.
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook